Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,631 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune checkpoint inhibitor-associated celiac disease.
Badran YR, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, Kem M, Zheng H, Borowsky J, Misdraji J, Mino-Kenudson M, Dougan M. Badran YR, et al. Among authors: zheng h. J Immunother Cancer. 2020 Jun;8(1):e000958. doi: 10.1136/jitc-2020-000958. J Immunother Cancer. 2020. PMID: 32581063 Free PMC article.
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Zhu AX, et al. Among authors: zheng h. Cancer. 2011 Nov 15;117(22):5094-102. doi: 10.1002/cncr.26165. Epub 2011 Apr 27. Cancer. 2011. PMID: 21538343 Free PMC article. Clinical Trial.
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. Goyal L, et al. Among authors: zheng h. Cancer. 2017 Jun 1;123(11):1979-1988. doi: 10.1002/cncr.30571. Epub 2017 Feb 13. Cancer. 2017. PMID: 28192597 Free PMC article. Clinical Trial.
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.
Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Kamran SC, et al. Among authors: zheng h. Cancer Med. 2018 Jul;7(7):2934-2942. doi: 10.1002/cam4.1558. Epub 2018 May 17. Cancer Med. 2018. PMID: 29771009 Free PMC article.
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ. de Klerk LK, et al. Among authors: zheng h. J Immunother Cancer. 2021 Sep;9(9):e002472. doi: 10.1136/jitc-2021-002472. J Immunother Cancer. 2021. PMID: 34593617 Free PMC article. Clinical Trial.
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX. Hezel AF, et al. Among authors: zheng h. Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24. Br J Cancer. 2014. PMID: 24960403 Free PMC article. Clinical Trial.
16,631 results
You have reached the last available page of results. Please see the User Guide for more information.